Today, the cornerstone of modern oncology is the discovery of targeted therapies. Although with fewer toxicities compared to conventional chemotherapy, the cutaneous adverse effects can determine the limitation of doses or even the interruption of treatment.
EGFR inhibitors produce numerous adverse skin reactions. Currently, EGFR inhibitors play an essential role in the oncological therapeutic arsenal, being used in the treatment of the following cancers: head and neck, lung, colon, prostate, breast, ovary, pancreas. Thus, recognizing the clinical signs, understanding the mechanism by which these adverse skin reactions occur, and most important knowing how to manage them is of great importance for all dermatologists.